Shionogi & Co., Ltd.

What's New Index

2012/02/03		Audio Webcasting of Conference Call for the Third Quarter of Fiscal Year 2011
2012/01/30		Shionogi Establishes a Developmental Subsidiary in EU
2012/01/30		Financial Results for the Third Quarter of Fiscal Year 2011
2012/01/25		Shionogi Inc. Press Release: STUDY DATA SHOW CUVPOSA® REDUCED CHRONIC SEVERE DROOLING IN PATIENTS AGES 3-16 YEARS-OLD WITH NEUROLOGIC CONDITIONS
2012/01/18		Shionogi Receives Approval of Injectable Analgesics for Cancer Pain, "OxiFast® Injection 10mg" and "OxiFast® Injection 50mg"
2011/12/12		Ezose Sciences Inc. Press Release: Ezose Sciences in New Agreement with Merck to Advance Glycan Biomarker Discovery in Diabetes
2011/12/08		Shionogi & Co., Ltd. and Shionogi Inc. Announce a Favorable Decision in FORTAMET® Preliminary Injunction Proceedings
2011/12/06		Ezose Sciences Inc. Press Release: Ezose Sciences Aligns to Add Diagnostics Capabilities to Its Core Biomarker Discovery Programs - Kiyoshi Nagata Named Chairman and CEO of Ezose -
2011/11/29		Shionogi Launches Carbapenem-Type Antibiotic,"Finibax® 0.5g for Intravenous Drip Infusion"
2011/11/28		Shionogi to Announce Corporate Reorganization and Personnel Reassignment
2011/11/18		Shionogi and Shire to Collaborate on the Development and Commercialization of the Therapeutic Agents for Attention-Deficit/Hyperactivity Disorder
2011/11/07		Audio Webcasting of Conference for the Second Quarter of Fiscal Year 2011

Press Release Index

Shionogi & Co., Ltd. has continuously supplied superior pharmaceuticals to people everywhere, based on its company policy to “constantly strive to provide medicine of the best possible kind essential for protection of the health of the people.